Victoria Ardiles

Dr. Victoria Ardiles


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2012 in Updates in Surgery
Verified
Journal Article
Closed access
PDF file
SSSofía Sala
Sofía Sala
VAVictoria Ardiles
Victoria Ardiles
MUMarina Ulla
Marina Ulla
FAFernando Alvarez
Fernando Alvarez
JPJuan Pekolj
Juan Pekolj
ESEduardo de Santibañes
Eduardo de Santibañes

1 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
FNFrancisco Calderon Novoa
Francisco Calderon Novoa
VAVictoria Ardiles
Victoria Ardiles
ESEduardo de Santibañes
Eduardo de Santibañes
JPJuan Pekolj
Juan Pekolj
JGJeremias Goransky
Jeremias Goransky
MSMartin de Santibanes
Martin de Santibanes
Colorectal cancer is the third most common cancer worldwide, and up to 50% of all patients diagnosed will develop metastatic disease. Management of colorectal liver metastases (CRLM) has been constantly improving, aided by newer and more effective chemotherapy agents and the use of multidisciplinary teams. However, the only curative treatment remains surgical resection of the CRLM. Although survival for surgically resected patients has shown modest improvement, this is mostly because of the fact that what is constantly evolving is the indication for resection. Surgeons are constantly pushing the limits of what is considered resectable or not, thus enhancing and enlarging the pool of patients who can be potentially benefited and even cured with aggressive surgical procedures. There are a variety of procedures that have been developed, which range from procedures to stimulate hepatic growth, such as portal vein embolization, two-staged hepatectomy, or the association of both, to technically challenging procedures such as simultaneous approaches for synchronous metastasis, ex-vivo or in-situ perfusion with total vascular exclusion, or even liver transplant. This article reviewed the major breakthroughs in liver surgery for CRLM, showing how much has changed and what has been achieved in the field of CRLM.

24 October 2012 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
VAVictoria Ardiles
Victoria Ardiles
MCMiguel A. Ciardullo
Miguel A. Ciardullo
DDDaniel D’aGostino
Daniel D’aGostino
JPJuan Pekolj
Juan Pekolj
FMFrancisco J. Mattera
Francisco J. Mattera
ESEduardo de Santibañes
Eduardo de Santibañes

22 November 2012 in Hepatogastroenterology
Verified
Journal Article
Closed access
MUMarina Ulla
Marina Ulla
VAVictoria Ardiles
Victoria Ardiles
ELEzequiel Levy-Yeyati
Ezequiel Levy-Yeyati
FAFernando A Alvarez
Fernando A Alvarez
JSJuan C Spina
Juan C Spina
ESEduardo De Santibañes
Eduardo De Santibañes
To describe the role of MDCT-volumetry to monitor and predict liver hypertrophy in a recently introduced surgical technique in patients needing hepatectomy. This prospective study was approved by the local research and ethics committee and patient informed consent was obtained. Twelve consecutive patients were selected for associating liver partition and portal vein ligation for staged-hepatectomy procedure. The mean absolute the future-liver-remnant (FLR) and FLR/total liver volume (TLV) ratio was calculated before and after surgery to determine the degree of hypertrophy. Six days after surgery a new CT-examination was performed to determine the FLR-volume and FLR/TLV. If the enlargement of the FLR was the expected a second-step surgery was performed. Continuous variables are expressed as mean (range). A p<0.05 was considered significant. The mean pre-operative FLR-volume was 402 mL and the FLR/TLV was 27%. The mean post-operative FLR-volume 6 days after the first step was 702 mL (range 521-1030 mL) being the mean difference between preoperative and postoperative FLR volume 303 mL (p<0.0001). The mean volume increase was 80% ranged from 21-139%. At day six, FLR/TLV was 46.5% (range 33.5-67.7), morbidity was 41% and mortality 0%. MDCT-volumetry has a key role in decision-making, monitoring and predicting liver hypertrophy pre- and postoperatively.

1 October 2015 in JAMA Surgery
Verified
Journal Article
Closed access
PDF file
ESEduardo de Santibañes
Eduardo de Santibañes
VAVictoria Ardiles
Victoria Ardiles
FAFernando A. Alvarez
Fernando A. Alvarez
Liver resection is the treatment of choice and a hope for cure for patients with malignant liver tumors. Resection is many times limited by the amount of future liver remnant, with liver failure being the most severe complication after major resections. To minimize this risk and expand resectability, portal vein occlusion of the tumor-bearing lobe is used to redistribute portal flow and induce hypertrophy of contralateral healthy parenchyma. Right portal vein embolization (PVE) is best used before surgery when the future liver remnant is tumor free, while portal vein ligation (PVL) is usually applied as part of 2-stage procedures for patients with bilobar disease who initially require tumor removal in the liver remnant. Around 20% to 40% hypertrophy can be achieved in 8 to 12 weeks with these strategies. However, up to 40% of patients never arrive to tumor resection either because of disease progression or insufficient hypertrophy during these long interval periods.

7 February 2013 in Current Colorectal Cancer Reports
Verified
Journal Article
Closed access
PDF file
FAFernando A. Alvarez
Fernando A. Alvarez
VAVictoria Ardiles
Victoria Ardiles
ESEduardo de Santibañes
Eduardo de Santibañes